Patent landscape of molecular and cellular targeted therapies for recessive dystrophic epidermolysis bullosa

References

• Fine J-D, Eady RAJ, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): report of the third international consensus meeting on diagnosis and classification of EB [Internet]. J Am Acad Dermatol. 2008 [cited 2017 Jul 6];58:931–950. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18374450
   PubMed Web of Science ®Google Scholar
• Mallipeddi R, Bleck O, Mellerio JE, et al. Dilemmas in distinguishing between dominant and recessive forms of dystrophic epidermolysis bullosa [Internet]. Br J Dermatol. 2003 [cited 2019 Mar 26];149:810–818.
   PubMed Web of Science ®Google Scholar
• Parente MG, Chung LC, Ryynanen J, et al. Human type VII collagen: cDNA cloning and chromosomal mapping of the gene [Internet]. Proc Natl Acad Sci USA. 1991 [cited 2019 Mar 26]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC52207/pdf/pnas01066-0041.pdf
   PubMed Web of Science ®Google Scholar
• Ryyninen J, Sollberg S, Parente MG, et al. Type VII collagen gene expression by cultured human cells and in fetal skin abundant mRNA and protein levels in epidermal keratinocytes [Internet]. J Clin Invest. 1992 [cited 2019 Mar 26];89:163–168. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442832/pdf/jcinvest00045-0177.pdf
   Web of Science ®Google Scholar
• LunstrumS GP, KuoS H-J, RosenbaumS LM, et al. Anchoring fibrils contain the carboxyl-terminal globular domain of type VI1 procollagen, but lack the amino-terminal globular domain* [Internet]. J Biol Chem. 1987 [cited 2019 Mar 26];262:13706–13712. Available from: https://pdfs.semanticscholar.org/b2f4/01efa7e8c52d5185822603f7c7c39853c468.pdf
   PubMed Web of Science ®Google Scholar
• Gordon MK, Hahn RA. Collagens [Internet]. Cell Tissue Res. 2010 [cited 2019 Mar 26];339:247–257.
   PubMed Web of Science ®Google Scholar
• Richer BC, Seeger K. The hinge region of type VII collagen is intrinsically disordered [Internet]. Matrix Biol. 2014 [cited 2019 Apr 2];36:77–83. Available from: https://www.sciencedirect.com/science/article/pii/S0945053X14000651?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Myllyharju J. Intracellular post-translational modifications of collagens. Berlin, Heidelberg: Springer;2005 [cited 2019 Mar 26]. p. 115–147. DOI:10.1007/b103821
   Google Scholar
• Ruotsalainen H, Sipilä L, Vapola M, et al. Glycosylation catalyzed by lysyl hydroxylase 3 is essential for basement membranes [Internet]. J Cell Sci. 2006 [cited 2019 Mar 26];119:625–635. Available from: http://jcs.biologists.org/content/119/4/625.long
   PubMed Web of Science ®Google Scholar
• Shoulders MD, Raines RT. Collagen structure and stability [Internet]. Annu Rev Biochem. 2009 [cited 2019 Mar 26];78:929–958.
   PubMed Web of Science ®Google Scholar
• Burgeson RE. Type VII collagen, anchoring fibrils, and epidermolysis bullosa [Internet]. J Invest Dermatol. 1993 [cited 2019 Mar 26];101:252–255. Available from: https://www.sciencedirect.com/science/article/pii/S0022202X9390521I?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Bruckner-Tuderman L, Höpfner B, Hammami-Hauasli N. Biology of anchoring fibrils: lessons from dystrophic epidermolysis bullosa [Internet]. Matrix Biol. 1999 [cited 2018 Apr 16];18:43–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10367730
   PubMed Web of Science ®Google Scholar
• Wertheim-Tysarowska K, Sobczyńska-Tomaszewska A, Kowalewski C, et al. The COL7A1 mutation database [Internet]. Hum Mutat. 2012 [cited 2019 Mar 26];33:327–331.
   PubMed Web of Science ®Google Scholar
• van Den Akker PC, Jonkman MF, Rengaw T, et al. The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations [Internet]. Hum Mutat. 2011 [cited 2019 Mar 26];32:1100–1107.
   PubMed Web of Science ®Google Scholar
• Bruckner-Tuderman L. Dystrophic epidermolysis bullosa: pathogenesis and clinical features [Internet]. Dermatol Clin. 2010 [cited 2019 Mar 26];28:107–114. Available from: https://www.sciencedirect.com/science/article/pii/S0733863509000941?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Fine J-D, Johnson LB, Weiner M, et al. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB registry experience, 1986-2006 [Internet]. J Am Acad Dermatol. 2009 [cited 2019 Mar 26];60:203–211. Available from: https://www.sciencedirect.com/science/article/pii/S0190962208012164?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Shinkuma S. Dystrophic epidermolysis bullosa: a review [Internet]. Clin Cosmet Investig Dermatol. 2015 [cited 2018 Jul 26];8:275–284. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26064063
   PubMed Web of Science ®Google Scholar
• Fine J-D. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the national epidermolysis bullosa registry [Internet]. JAMA Dermatol. 2016 [cited 2019 Mar 26];152:1231.
   PubMed Web of Science ®Google Scholar
• Soro L, Bartus C, Purcell S. Recessive dystrophic epidermolysis bullosa: a review of disease pathogenesis and update on future therapies [Internet]. J Clin Aesthet Dermatol. 2015 [cited 2019 Mar 26];8:41–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26029334
   PubMedGoogle Scholar
• Ramirez MN, Murrell DF, Fine J-D. Management of epidermolysis bullosa [Internet]. Expert Opin Orphan Drugs. 2013 [cited 2019 Mar 26];1:279–293.
   Web of Science ®Google Scholar
• Eguizabal C, Aran B, Chuva de Sousa Lopes SM, et al. Two decades of embryonic stem cells: a historical overview [Internet]. Hum Reprod Open. 2019 [cited 2019 Apr 2]. DOI:10.1093/hropen/hoy024/5304018
   PubMedGoogle Scholar
• Tamai K, Uitto J. Stem cell therapy for epidermolysis bullosa – does it work? [Internet]. J Invest Dermatol. 2016 [cited 2019 Mar 26];136:2119–2121. Available from: https://www.sciencedirect.com/science/article/pii/S0022202X1632111X?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Peking P, Koller U, Murauer EM. Functional therapies for cutaneous wound repair in epidermolysis bullosa [Internet]. Adv Drug Deliv Rev. 2018 [cited 2019 Mar 26];129:330–343. Available from: https://www.sciencedirect.com/science/article/pii/S0169409X1730306X?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Petrof G, Lwin SM, Martinez-Queipo M, et al. Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa [Internet]. J Invest Dermatol. 2015 [cited 2018 Jul 26];135:2319–2321. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25905587
   PubMed Web of Science ®Google Scholar
• Conget P, Rodriguez F, Kramer S, et al. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa [Internet]. Cytotherapy. 2010 [cited 2018 Jul 26];12:429–431. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20230217
   PubMed Web of Science ®Google Scholar
• Cooper ML, Hansbrough JF, Spielvogel RL, et al. In vivo optimization of a living dermal substitute employing cultured human fibroblasts on a biodegradable polyglycolic acid or polyglactin mesh [Internet]. Biomaterials. 1991 [cited 2019 Mar 26];12:243–248. Available from: https://www.sciencedirect.com/science/article/pii/014296129190207Q
   PubMed Web of Science ®Google Scholar
• Ganier C, Titeux M, Gaucher S, et al. Intradermal injection of bone marrow mesenchymal stromal cells corrects recessive dystrophic epidermolysis bullosa in a xenograft model [Internet]. J Invest Dermatol. 2018 [cited 2019 Apr 2];138:2483–2486. Available from: https://www.sciencedirect.com/science/article/pii/S0022202X18319651?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Kiritsi D, Nyström A. Recent advances in understanding and managing epidermolysis bullosa [Internet]. F1000Res. 2018 [cited 2019 Apr 2];7:1097. Available from: https://f1000research.com/articles/7-1097/v1
   Google Scholar
• Wong T, Gammon L, Liu L, et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa [Internet]. J Invest Dermatol. 2008 [cited 2019 Mar 26];128:2179–2189. Available from: https://www.sciencedirect.com/science/article/pii/S0022202X15340264?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Petrof G, Martinez-Queipo M, Mellerio JE, et al. Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial Funding sources [Internet]. Br J Dermatol. 2013 [cited 2019 Jan 21];169:1025–1033. Available from: www.controlled-trials
   PubMed Web of Science ®Google Scholar
• Rashidghamat E, McGrath JA. Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa [Internet]. Intractable Rare Dis Res. 2017 [cited 2018 Aug 20];6:6–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28357176
   PubMed Web of Science ®Google Scholar
• Wagner JE, Ishida-Yamamoto A, McGrath JA, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa [Internet]. N Engl J Med. 2010 [cited 2018 Jul 26];363:629–639.
   PubMed Web of Science ®Google Scholar
• Tolar J, Wagner JE. Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix [Internet]. Lancet. 2013 [cited 2019 Mar 26];382:1214–1223. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24095195
   PubMed Web of Science ®Google Scholar
• Naughton GK, Naughton BA; Advanced BioHealing Inc. Three-dimensional cell and tissue culture system. US4963489A. 1990 Oct 16.
   Google Scholar
• Lee S, Kim M; Anterogen CO Ltd. Mesenchymal stem cells-hydrogel-biodegradable or mesenchymal stem cells-hydrogel-nondegradable support composition for alleviating or improving epidermolysis bullosa. US20180117217A1. 2018 May 03.
   Google Scholar
• Hart CE, Loewen-Rodriguez A, Lessem J. Dermagraft: use in the treatment of chronic wounds [Internet]. Adv Wound Care (New Rochelle). 2012 [cited 2019 Mar 26];1:138–141. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623576/pdf/wound.2011.0282.pdf
   PubMedGoogle Scholar
• Perdoni C, Osborn MJ, Tolar J. Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa [Internet]. Transl Res. 2016 [cited 2019 Mar 26];168:50–58. Available from: https://www.sciencedirect.com/science/article/pii/S1931524415001759?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Sebastiano V, Zhen HH, Haddad B, et al. Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa [Internet]. Sci Transl Med. 2014 [cited 2019 Mar 27];6:264ra163. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25429056
   PubMed Web of Science ®Google Scholar
• Siprashvili Z, Nguyen NT, Gorell ES, et al. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa [Internet]. JAMA. 2016 [cited 2018 Jul 26];316:1808. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27802546
   PubMed Web of Science ®Google Scholar
• Ortiz-Urda S, Lin Q, Green CL, et al. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue [Internet]. J Clin Invest. 2003 [cited 2019 Mar 26];111:251–255. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12531881
   PubMed Web of Science ®Google Scholar
• Siprashvili Z, Nguyen NT, Bezchinsky MY, et al. Long-term type VII collagen restoration to human epidermolysis bullosa skin tissue [Internet]. Hum Gene Ther. 2010 [cited 2017 Aug 31];21:1299–1310. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20497034
   PubMed Web of Science ®Google Scholar
• Woodley DT, Keene DR, Atha T, et al. Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo [Internet]. Mol Ther. 2004 [cited 2018 Mar 11];10:318–326. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1525001604001844
   PubMed Web of Science ®Google Scholar
• Marinkovich PM; The Board Of Trustees Of The Leland Stanford Junior University. Treatment of epidermolysis bullosa by injection of autologous collagen vii overexpressing leukocytes. WO2017075248A1. 2017 May 04.
   Google Scholar
• Siprashvili Z, Nguyen NT, Marinkovich MP, et al.; The Board Of Trustees Of The Leland Stanford Junior University. Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes. WO2017120147A1. 2017 Jul 13.
   Google Scholar
• Dailey V, Chakiath M, Zhang S, et al.; Intrexon Corporation. Compositions and methods for treatment of type vii collagen deficiencies. WO2017161180A1. 2017 Sep 21.
   Google Scholar
• Krishnan S, Agarwal P; Krystal Biotech Inc. Compositions and methods for the treatment of wounds, disorders, and diseases of the skin. US9877990B2. 2018 Jan 30.
   Google Scholar
• Bauer J, Mitchell LG Recombinant gene expression: reviews and protocols. US8735366B2. 2014 May 27.
   Google Scholar
• Mitchell LG, Puttaraju M, Dallinger G, et al.; Intronn, Inc. Spliceosome mediated rna trans-splicing for correction of skin disorders. WO2004006678A1. 2004 Jan 22.
   Google Scholar
• Lundberg AS, Kulkarni S, Klein L, et al.; CRISPR Therapeutics Ag. Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders. WO2018154413A1. 2016 Aug 18.
   Google Scholar
• Osborn MJ, Tolar J, Blazar B, et al.; University of Minnesota. TALEN-based gene correction. US9393257B2. 2016 Jul 19.
   Google Scholar
• Webber BR, Osborn MJ, Tolar J, et al.; University of Minnesota. Method for correcting a genetic sequence. US20180142262A1. 2018 May 24.
   Google Scholar
• Wally V, Murauer EM, Bauer JW. Spliceosome-mediated trans-splicing: the therapeutic cut and paste. J Invest Dermatol. 2012 [cited 2019 Mar 26];132:1959–1966. Available from: https://www.sciencedirect.com/science/article/pii/S0022202X15358565?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Tockner B, Kocher T, Hainzl S, et al. Construction and validation of an RNA trans-splicing molecule suitable to repair a large number of COL7A1 mutations [Internet]. Gene Ther. 2016 [cited 2019 Mar 26];23:775–784. Available from: http://www.nature.com/articles/gt201657
   PubMed Web of Science ®Google Scholar
• Peking P, Koller U, Duarte B, et al. An RNA-targeted therapy for dystrophic epidermolysis bullosa [Internet]. Nucleic Acids Res. 2017 [cited 2019 Jan 16];45:10259–10269. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28973459
   PubMed Web of Science ®Google Scholar
• Peking P, Koller U, Hainzl S, et al. A gene gun-mediated nonviral RNA trans-splicing strategy for Col7a1 repair [Internet]. Mol Ther Nucleic Acids. 2016 [cited 2019 Mar 26];5:e287. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26928235
   PubMedGoogle Scholar
• Kumar M, Keller B, Makalou N, et al. Systematic determination of the packaging limit of lentiviral vectors [Internet]. Hum Gene Ther. 2001 [cited 2019 Mar 27];12:1893–1905.
   PubMed Web of Science ®Google Scholar
• Georgiadis C, Syed F, Petrova A, et al. Lentiviral engineered fibroblasts expressing codon-optimized COL7A1 restore anchoring fibrils in RDEB [Internet]. J Invest Dermatol. 2016 [cited 2019 Jan 16];136:284–292. Available from: https://www.sciencedirect.com/science/article/pii/S0022202X15000275?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Yang L, Mali P, Kim-Kiselak C, et al. CRISPR-cas-mediated targeted genome editing in human cells. Totowa, NJ: Humana Press; 2014 [cited 2019 Feb 10]. p. 245–267. DOI:10.1007/978-1-62703-761-7_16
   Google Scholar
• Woodley DT, Keene DR, Atha T, et al. Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa [Internet]. Nat Med. 2004 [cited 2017 Jul 6];10:693–695.
   PubMed Web of Science ®Google Scholar
• Remington J, Wang X, Hou Y, et al. Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa [Internet]. Mol Ther. 2009 [cited 2017 Jul 6];17:26–33. Available from: http://linkinghub.elsevier.com/retrieve/pii/S152500161631471X
   PubMed Web of Science ®Google Scholar
• Wang X, Ghasri P, Amir M, et al. Topical application of recombinant type VII collagen incorporates into the dermal–epidermal junction and promotes wound closure [Internet]. Mol Ther. 2013 [cited 2017 May 26];21:1335–1344. Available from: http://www.sciencedirect.com/science/article/pii/S152500161631958X
   PubMed Web of Science ®Google Scholar
• Woodley DT, Wang X, Amir M, et al. Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa [Internet]. J Invest Dermatol. 2013 [cited 2017 Jul 14];133:1910–1913. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022202X15363144
   PubMed Web of Science ®Google Scholar
• Viswanathan M, DeSouza M; Phoenix Tissue Repair Inc. Collagen 7 and related methods. US9676837B2. 2017 Jun 13.
   Google Scholar
• Chen M, Woodley D, de Souza M; Phoenix Tissue Repair Inc University of Southern California (USC). Recombinant C7 and methods of use. US20140031295A1. 2014 Jan 30.
   Google Scholar
• Hou Y, Guey LT, Wu T, et al. Intravenously administered recombinant human type VII collagen derived from chinese hamster ovary cells reverses the disease phenotype in recessive dystrophic epidermolysis bullosa mice [Internet]. J Invest Dermatol. 2015 [cited 2017 May 22];135:3060–3067. Available from: http://www.sciencedirect.com/science/article/pii/S0022202X15601579
   PubMed Web of Science ®Google Scholar
• Quinones-Garcia I, Guey L, Lowe K, et al.; Shire Human Genetic Therapies, Inc. Collagen 7 compositions and methods of using the same. WO2017112757A1. 2017 Jun 29.
   Google Scholar
• Quinones-Garcia I, Simeone B, Lillie R, et al.; Shire Human Genetic Therapies, Inc. Methods of purifying collagen 7. WO2017160636A1. 2017 Sep 21.
   Google Scholar
• Marinkovich MP, Lane AT, Rajadas J; Leland Stanford Junior University US Department of Veterans Affairs. Production and delivery of a stable collagen. US9403895B2. 2016 Aug 02.
   Google Scholar
• Goto M, Sawamura D, Nishie W, et al. Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients [Internet]. J Invest Dermatol. 2006 [cited 2019 Feb 10];126:2614–2620. Available from: https://www.sciencedirect.com/science/article/pii/S0022202X15326981?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Turczynski S, Titeux M, Pironon N, et al. Antisense-mediated exon skipping to reframe transcripts. In: Humana Press. Exon Skipping - Methods and Protocols. 233 Spring Street, New York, NY 10013, USA; 2012 [cited 2019 Mar 27]. p. 221–238. DOI:10.1007/978-1-61779-767-5_15
   Google Scholar
• Turczynski S, Titeux M, Tonasso L, et al. Targeted exon skipping restores type VII collagen expression and anchoring fibril formation in an in vivo RDEB model [Internet]. J Invest Dermatol. 2016 [cited 2019 Mar 27];136:2387–2395. Available from: https://www.sciencedirect.com/science/article/pii/S0022202X16322370?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Lim KRQ, Echigoya Y, Nagata T, et al. Efficacy of multi-exon skipping treatment in duchenne muscular dystrophy dog model neonates [Internet]. Mol Ther. 2019 [cited 2019 Mar 27];27:76–86. Available from: https://www.sciencedirect.com/science/article/pii/S1525001618305008?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Hovnanian A, Titeux M, Turczynski S; Institut National de la Sante et de la Recherche Medicale INSERM. Exon skipping therapy for dystrophic epidermolysis bullosa. US9340783B2. 2016 May 17.
   Google Scholar
• Pasmooij AMG, Van Den Akker PC, Bremer J, et al.; Rijksuniversiteit Groningen, Academisch Ziekenhuis Groningen. Antisense oligonucleotide-mediated exon skipping as systemic therapy for recessive dystrophic epidermolysis bullosa (rdeb). WO2017078526A2. 2017 May 11.
   Google Scholar
• Haisma EM, Potman M, Platenburg GJ; ProQR Therapeutics II BV. Antisense oligonucleotides to treat dystrophic epidermolysis bullosa. US20180245078A1. 2018 Aug 30. 2016.
   Google Scholar
• Marlene HE, Potman M, Beumer W, et al.; ProQR Therapeutics II BV. Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy. US20180216106A1. 2018 Aug 02;
   Google Scholar
• Mourich DV; Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type vii collagen. WO2016196670A1. 2016 Dec 08. 2016.
   Google Scholar
• Gekeler V, Gimmnich P, Hofmann H-P, et al. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice [Internet]. Oligonucleotides. 2006 [cited 2019 Mar 27];16:83–93.
   PubMed Web of Science ®Google Scholar
• Zingman LV, Park S, Olson TM, et al. Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy [Internet]. Clin Pharmacol Ther. 2007 [cited 2019 Feb 10];81:99–103.
   PubMed Web of Science ®Google Scholar
• Bhatnagar R, Brenner S; University of California. Nonsense suppressor agents in treatment of cutaneous and gastrointestinal disorders. US20050261210A1. 2005 Nov 24.
   Google Scholar
• Chen M, Woodley D; University of Southern California (USC). Methods and agents for enhancing wound healing [Internet]. US20130237485A1. 2013 Sep 12. 2011 [cited 2019 Mar 30]. Available from: https://patents.google.com/patent/US20130237485A1/3Den.
   Google Scholar
• Singh A, Ursic D, Davies J. Phenotypic suppression and misreading in saccharomyces cerevisiae [Internet]. Nature. 1979 [cited 2019 Mar 27];277:146–148. Available from: http://www.nature.com/articles/277146a0
   PubMed Web of Science ®Google Scholar
• Barton-Davis ER, Cordier L, Shoturma DI, et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice [Internet]. J Clin Invest. 1999 [cited 2019 Mar 27];104:375–381. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10449429
   PubMed Web of Science ®Google Scholar
• Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line [Internet]. Nat Med. 1997 [cited 2019 Mar 27];3:1280–1284. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9359706
   PubMed Web of Science ®Google Scholar
• Wagner KR, Hamed S, Hadley DW, et al. Gentamicin treatment of duchenne and becker muscular dystrophy due to nonsense mutations [Internet]. Ann Neurol. 2001 [cited 2019 Mar 27];49:706–711.
   PubMed Web of Science ®Google Scholar
• Chen M, Woodley D; University of Southern California. Methods and agents to enhance wound healing. JP6316878B2. 2018 Apr 25.
   Google Scholar
• Shalev M, Baasov T. When proteins start to make sense: fine-tuning aminoglycosides for PTC suppression therapy [Internet]. Med Chem Commun. 2014 [cited 2019 Mar 27];5:1092–1105. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25147726
   Google Scholar
• Roberge M, Baradaran-Heravi A, Zimmerman CD, et al.; University of British Columbia. Suppressors of premature termination codons as therapeutics and methods for their use. US20180258123A1. 2018 Sep 13.
   Google Scholar
• Roberge M, Baradaran-Heravi A, Balgi AD, et al.; The Centre For Drug Research And Development, The University Of British Columbia. Compositions for promoting readthrough of premature termination codons, and methods of using the same. WO2017049409A1. 2017 Mar 30. 2016.
   Google Scholar
• Lejeune F, Deprez B, Beghyn T, et al.; Institut National de la Sante et de la Recherche Medicale INSERM. Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound. US20130217717A1/US9913829B2. 2018 Mar 13.
   Google Scholar
• Gatti R, Du L, Damoiseaux R, et al.; University of California. Premature-termination-codons readthrough compounds. US9255088B2. 2016 Feb 09.
   Google Scholar
• Atanasova VS, Jiang Q, Prisco M, et al. Amlexanox enhances premature termination codon read-through in COL7A1 and expression of full length type VII collagen: potential therapy for recessive dystrophic epidermolysis bullosa [Internet]. J Invest Dermatol. 2017 [cited 2019 Apr 2];137:1842–1849. Available from: https://www.sciencedirect.com/science/article/pii/S0022202X17315506?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations [Internet]. Nature. 2007 [cited 2019 Mar 27];447:87–91. Available from: http://www.nature.com/articles/nature05756
   PubMed Web of Science ®Google Scholar
• Almstead N, Chen G, Karp GM, et al.; PTC Therapeutics Inc. Compounds for nonsense suppression, and methods for their use. US20170204073A1. 2017 Jul 20.
   Google Scholar
• Almstead N, Chen G, Hirawat S, et al.; PTC Therapeutics Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith. US9289398B2. 2016 Mar 22.
   Google Scholar
• Ryan NJ. Ataluren: first global approval [Internet]. Drugs. 2014 [cited 2019 Mar 27];74:1709–1714. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25193627
   PubMed Web of Science ®Google Scholar
• Kerem E, Konstan MW, De Boeck K, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial [Internet]. Lancet Respir Med. 2014 [cited 2019 Mar 27];2:539–547. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24836205
   PubMed Web of Science ®Google Scholar
• McDonald CM, Campbell C, Torricelli RE, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [Internet]. Lancet. 2017 [cited 2019 Mar 27];390:1489–1498. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28728956
   PubMed Web of Science ®Google Scholar
• Cogan J, Weinstein J, Wang X, et al. Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa [Internet]. Mol Ther. 2014 [cited 2019 Mar 27];22:1741–1752. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25155989
   PubMed Web of Science ®Google Scholar
• McElroy SP, Nomura T, Torrie LS, et al. A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays [Internet]. PLoS Biol. 2013 [cited 2019 Mar 27];11:e1001593. Petsko GA, editor.
   PubMed Web of Science ®Google Scholar
• Hovnanian A. Systemic protein therapy for recessive dystrophic epidermolysis bullosa: how far are we from clinical translation? [Internet]. J Invest Dermatol. 2013 [cited 2019 Mar 27];133:1719–1721. Available from: https://www.sciencedirect.com/science/article/pii/S0022202X15363120?via%3Dihub
   PubMed Web of Science ®Google Scholar
• McNally EM, Wyatt EJ. Welcome to the splice age: antisense oligonucleotide–mediated exon skipping gains wider applicability [Internet]. J Clin Invest. 2016 [cited 2019 Mar 27];126:1236–1238. Available from: https://www.jci.org/articles/view/86799
   PubMed Web of Science ®Google Scholar
• Akpulat U, Wang H, Becker K, et al. Shorter phosphorodiamidate morpholino splice-switching oligonucleotides may increase exon-skipping efficacy in DMD [Internet]. Mol Ther Nucleic Acids. 2018 [cited 2019 Mar 27];13:534–542. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30396145
   PubMedGoogle Scholar
• Goyenvalle A, Griffith G, Babbs A, et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers [Internet]. Nat Med. 2015 [cited 2019 Mar 27];21:270–275. Available from: http://www.nature.com/articles/nm.3765
   PubMed Web of Science ®Google Scholar
• Järver P, O’Donovan L, Gait MJ. A chemical view of oligonucleotides for exon skipping and related drug applications [Internet]. Nucleic Acid Ther. 2014 [cited 2019 Mar 27];24:37–47.
   PubMed Web of Science ®Google Scholar
• Wu W, Lu Z, Li F, et al. Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model [Internet]. Proc Natl Acad Sci U S A. 2017 [cited 2019 Apr 2];114:1660–1665. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28137859
   PubMed Web of Science ®Google Scholar
• Mencía Á, Chamorro C, Bonafont J, et al. Deletion of a pathogenic mutation-containing exon of COL7A1 allows clonal gene editing correction of RDEB patient epidermal stem cells [Internet]. Mol Ther Nucleic Acids. 2018 [cited 2019 Apr 2];11:68–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29858091
   PubMedGoogle Scholar
• Berger A, Maire S, Gaillard M-C, et al. mRNA trans-splicing in gene therapy for genetic diseases [Internet]. Wiley Interdiscip Rev RNA. 2016 [cited 2019 Mar 27];7:487–498. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27018401
   PubMed Web of Science ®Google Scholar
• Woodley DT, Cogan J, Hou Y, et al. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients [Internet]. J Clin Invest. 2017 [cited 2018 Jul 26];127:3028–3038. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28691931
   PubMed Web of Science ®Google Scholar
• Dabrowski M, Bukowy-Bieryllo Z, Zietkiewicz E. Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons [Internet]. Mol Med. 2018 [cited 2019 Mar 27];24:25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30134808
   PubMed Web of Science ®Google Scholar
• Wong AY-T, Mahalatchimy A. Human stem cells patents-emerging issues and challenges in Europe, United States, China, and Japan [Internet]. J World Intellect Prop. 2018 [cited 2019 Mar 27];21:326–355.
   Web of Science ®Google Scholar